1.Stage Differentiation and Treatment of Myasthenia Gravis Based on "Four-Dimensional Pivot-Earth" Qi Transformation Mode
Tianqi HUANG ; Shunning HUANG ; Liping ZHANG ; Changlin QIU ; Ruijie MA ; Kelin HE ; Hui QIU
Journal of Traditional Chinese Medicine 2025;66(11):1178-1181
The connotation of the "four-dimensional pivot-earth" qi transformation mode is a dialectical system of the ascending and descending of yin-yang qi movement, which presented as "the middle Jiao showing earth qi mediating, the left wheel showing water and wood ascending, and the right wheel showing fire and metal converting and descending". Based on this dialectical thinking, it is believed that the core pathogenesis of myasthenia gravis is deficiency of center qi and transportation failure to pivot-earth; the middle-stage characteristics of the disease progression are the loss of mediation of the central qi, resulting in water coldness and wood constraint, and clear yang failing to ascend; the final outcome of this disease is the loss of astringeing of lung metal and qi sinking. The treatment should be based on the rule of qi movement, so for the start-stage, Buzhong Yiqi Decoction (补中益气汤) should be used as the basis to nourish the earth and consolidate the root, and restrengthen the middle qi; for the middle-stage, herbs like Yingyanghuo (Epimedium brevicornu Maxim.), Bajitian (Morinda officinalis How) could be combined to warm the water and soothe the wood, raise yang and boost qi; for the final stage, plus Sini Decoction (四逆汤) to astringe metal to stop collapse, and powerfully supplement original qi. All these medicinals can promote pivot-earth re-transportation, four-dimensional transformation, and regular circulation of qi movement, so as to provide thoughts for improving the clinical effectiveness of myasthenia gravis.
2.Efficacy and safety analysis of ceftazidime/avibactam combined with amikacin in the treatment of severe pneumonia caused by CRE infection
Tianqi ZHANG ; Bi CHEN ; Cantang ZHANG
China Pharmacy 2025;36(21):2705-2710
OBJECTIVE To evaluate the efficacy and safety of ceftazidime/avibactam (CAZ/AVI) combined with amikacin (AMK) in the treatment of carbapenem-resistant Enterobacteriaceae (CRE) severe pneumonia. METHODS A retrospective cohort study was conducted on 240 patients diagnosed with severe pneumonia caused by CRE infection in the intensive care unit (ICU) of the Affiliated Hospital of Xuzhou Medical University from January 2022 to December 2024. The patients were divided into a combination group (CAZ/AVI combined with AMK, n=136) and a control group (CAZ/AVI alone, n=104). The 28-day mortality rate, clinical efficacy,mechanical ventilation time, ICU stay, infectious markers [C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), white blood cell count (WBC), and neutrophil percentage (N%)], Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores, and total incidence of adverse reactions were compared between two groups of patients. At the same time, subgroup analysis was conducted based on the severity of the condition, mechanical ventilation status, and baseline renal function. RESULTS The 28-day mortality rate of patients in the combination group was significantly lower than that in the control group (20.6% vs. 34.6%, P=0.022), and the clinical effective rate was significantly higher than that in the control group (80.1% vs. 65.4%, P=0.004). The mechanical ventilation time and ICU hospitalization time in the combination group were significantly shorter than those in the control group ([ 7.2±2.4) days vs. (10.4±3.6) days, (10.5±3.1) days vs. (13.7±3.8) days; P<0.01].After 7 days of treatment, the CRP, PCT, IL-6, WBC, N% and APACHE Ⅱ scores of patients in the combination group significantly decreased compared to before treatment, and the decrease was significantly greater than that of the control group (P<0.01). There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients (11.8% vs. 13.5%, P=0.690). Subgroup analysis showed that among high-risk (APACHE Ⅱ score≥15) and mechanically ventilated patients, the 28-day mortality rate and weaning time of the combination group were significantly lower/ shorter than those of the control group (P<0.05), while there was no significant difference in the total incidence of adverse reactions between the combination group and the control group after dose adjustment in patients with chronic renal insufficiency (P>0.05). CONCLUSIONS The CAZ/AVI combined with AMK regimen has better anti-infective efficacy and good safety in patients with severe pneumonia caused by CRE infection compared to the CAZ/AVI regimen alone; the survival benefits of this joint regimen are more significant in high-risk and mechanically ventilated patients, with critically ill patients being the main beneficiaries.
3.Effects of elastic modulus of the metal block on the condylar-constrained knee prosthesis tibial fixation stability.
Yuhan ZHANG ; Jing ZHANG ; Tianqi DONG ; Xuan ZHANG ; Weijie ZHANG ; Lei GUO ; Zhenxian CHEN
Journal of Biomedical Engineering 2025;42(4):782-789
Although metal blocks have been widely used for reconstructing uncontained tibial bone defects, the influence of their elastic modulus on the stability of tibial prosthesis fixation remains unclear. Based on this, a finite element model incorporating constrained condylar knee (CCK) prosthesis, tibia, and metal block was established. Considering the influence of the post-restraint structure of the prosthesis, the effects of variations in the elastic modulus of the block on the von Mises stress distribution in the tibia and the block, as well as on the micromotion at the bone-prosthesis fixation interface, were investigated. Results demonstrated that collision between the insert post and femoral prosthesis during tibial internal rotation increased tibial von Mises stress, significantly influencing the prediction of block elastic modulus variation. A decrease in the elastic modulus of the metal block resulted in increased von Mises stress in the proximal tibia, significantly reduced von Mises stress in the distal tibia, decreased von Mises stress of the block, and increased micromotion at the bone-prosthesis fixation interface. When the elastic modulus of the metal block fell below that of bone cement, inadequate block support substantially increased the risk of stress shielding in the distal tibia and fixation interface loosening. Therefore, this study recommends that biomechanical investigations of CCK prostheses must consider the post-constraint effect, and the elastic modulus of metal blocks for bone reconstruction should not be lower than 3 600 MPa.
Knee Prosthesis
;
Humans
;
Finite Element Analysis
;
Tibia/surgery*
;
Elastic Modulus
;
Arthroplasty, Replacement, Knee/methods*
;
Stress, Mechanical
;
Metals
;
Prosthesis Design
;
Knee Joint/surgery*
;
Biomechanical Phenomena
4.Differential Resting-State Brain Activity Following Early- and Late-Night Sleep Loss.
Tianqi DI ; Libo ZHANG ; Shiqiu MENG ; Yang GUO ; Wangyue LIU ; Enyu ZHENG ; Zhoulong YU ; Yan SUN ; Jie SHI
Neuroscience Bulletin 2025;41(9):1696-1700
5.Immunogenicity, safety and immune persistence of the sequential booster with the recombinant protein-based COVID-19 vaccine (CHO cell) in healthy people aged 18-84 years
Dingyan YAO ; Yingping CHEN ; Fan DING ; Xiaosong HU ; Zhenzhen LIANG ; Bo XING ; Yifei CAO ; Tianqi ZHANG ; Xilu WANG ; Yuting LIAO ; Juan YANG ; Huakun LYU
Chinese Journal of Preventive Medicine 2024;58(1):25-32
Objective:To evaluate the immunogenicity, safety, and immune persistence of the sequential booster with the recombinant protein-based COVID-19 vaccine (CHO cell) in healthy people aged 18-84 years.Methods:An open-label, multi-center trial was conducted in October 2021. The eligible healthy individuals, aged 18-84 years who had completed primary immunization with the inactivated COVID-19 vaccine 3 to 9 months before, were recruited from Shangyu district of Shaoxing and Kaihua county of Quzhou, Zhejiang province. All participants were divided into three groups based on the differences in prime-boost intervals: Group A (3-4 months), Group B (5-6 months) and Group C (7-9 months), with 320 persons per group. All participants received the recombinant COVID-19 vaccine (CHO cell). Blood samples were collected before the vaccination and after receiving the booster at 14 days, 30 days, and 180 days for analysis of GMTs, antibody positivity rates, and seroconversion rates. All adverse events were collected within one month and serious adverse events were collected within six months. The incidences of adverse reactions were analyzed after the booster.Results:The age of 960 participants was (52.3±11.5) years old, and 47.4% were males (455). The GMTs of Groups B and C were 65.26 (54.51-78.12) and 60.97 (50.61-73.45) at 14 days after the booster, both higher than Group A′s 44.79 (36.94-54.30) ( P value<0.05). The GMTs of Groups B and C were 23.95 (20.18-28.42) and 27.98 (23.45-33.39) at 30 days after the booster, both higher than Group A′s 15.71 (13.24-18.63) ( P value <0.05). At 14 days after the booster, the antibody positivity rates in Groups A, B, and C were 91.69% (276/301), 94.38% (302/320), and 93.95% (295/314), respectively. The seroconversion rates in the three groups were 90.37% (272/301), 93.75% (300/320), and 93.31% (293/314), respectively. There was no significant difference among these rates in the three groups (all P values >0.05). At 30 days after the booster, antibody positivity rates in Groups A, B, and C were 79.60% (238/299), 87.74% (279/318), and 90.48% (285/315), respectively. The seroconversion rates in the three groups were 76.92% (230/299), 85.85% (273/318), and 88.25% (278/315), respectively. There was a significant difference among these rates in the three groups (all P values <0.001). During the sequential booster immunization, the incidence of adverse events in 960 participants was 15.31% (147/960), with rates of about 14.38% (46/320), 17.50% (56/320), and 14.06% (45/320) in Groups A, B, and C, respectively. The incidence of adverse reactions was 8.02% (77/960), with rates of about 7.50% (24/320), 6.88% (22/320), and 9.69% (31/320) in Groups A, B, and C, respectively. No serious adverse events related to the booster were reported. Conclusion:Healthy individuals aged 18-84 years, who had completed primary immunization with the inactivated COVID-19 vaccine 3 to 9 months before, have good immunogenicity and safety profiles following the sequential booster with the recombinant COVID-19 vaccine (CHO cell).
6.Research progress on combined treatment of physical exercise and anti-hypertensive drugs for hypertension in elderly people
Tianqi ZHANG ; Chenxi XIA ; Hong SHI ; Yatong ZHANG
Chinese Journal of Geriatrics 2024;43(3):395-400
Hypertension has a high prevalence in China, and the predominant reliance on drug treatment consumes enormous medical resources.Physical exercise is the only widely-accepted nonpharmacologic therapy for hypertension and is potentially cost-effective.How to incorporate exercise into a prescription for rational treatment of hypertension is a topic that needs to be addressed.This review examines the research progress on the treatment of hypertension combining physical exercise with anti-hypertensive drugs in elderly people, aiming to provide some information and options to promote personalized treatment strategies for hypertension in elderly people.
7.Research advances in second-line therapies for hepatocellular carcinoma after resistance to targeted therapy combined with immunotherapy
Tianqi ZHANG ; Yuzhe CAO ; Mengxuan ZUO ; Yangkui GU
Journal of Clinical Hepatology 2024;40(2):386-390
In recent years, clinical studies on targeted therapy and immunotherapy for advanced hepatocellular carcinoma used alone or in combination have provided abundant evidence on efficacy and safety for the selection of first-line therapies. However, no consensus has been reached on the selection of second-line therapies in various clinical guidelines for hepatocellular carcinoma, which is caused by the fact that existing evidence is limited to the options after failure of sorafenib and that there is still a lack of high-level evidence for new first-line therapies such as second-line therapies after resistance to targeted therapy and immunotherapy for hepatocellular carcinoma. This article reviews the results of current clinical trials and summarizes the studies on second-line therapies for hepatocellular carcinoma after resistance to first-line targeted therapy and immunotherapy for hepatocellular carcinoma based on the different mechanisms of action of drugs, as well as the research advances in recent years. For hepatocellular carcinoma patients with resistance to first-line targeted therapy and immunotherapy, targeted combination therapy and dual-immune therapy are expected to improve treatment outcome and survival, and more prospective clinical studies are needed in the future to provide effective and safe treatment regimens for hepatocellular carcinoma patients with resistance to targeted therapy and immunotherapy.
8.Development of an experience scale for patients with chronic wound debridement and dressing
Yanping SHI ; Ling TIAN ; Zhifei LIU ; Wei ZHANG ; Tianqi LIU ; Jinna WANG ; Siming JIANG ; Yanan CUI ; Zirong LI
Chinese Journal of Medical Aesthetics and Cosmetology 2024;30(3):213-217
Objective:To develop and evaluate a medical experience assessment scale for debridement and dressing change in chronic wound patients in China, and to provide a reference for improving hospital service quality.Methods:Based on the framework of hospital consumer assessment of healthcare providers and systems survey (HCAHPS) in the United States, a preliminary draft of the scale was formed through a literature review and qualitative interviews with 12 chronic wound patients (7 males and 5 females aged 58.1±12.3 years). Five experts were invited for content validity testing, and 191 chronic wound patients (111 males and 80 females aged 53.5±19.1 years) were selected to evaluate the internal consistency reliability, half reliability, retest reliability, and structural validity of the scale.Results:The Chronic Wound Patient Debridement and Dressing Experience Scale covered 5 dimensions with 30 sub-items and 2 comprehensive evaluation items, including demand response, good and friendly communication, professional trust, optimization of the medical treatment process, and encouragement of patient participation. The scale Cronbach′s α coefficient was 0.967 and ranged from 0.890 to 0.962 for each dimension. The overall retest reliability of the scale was 0.940 and ranged from 0.895 to 0.940 for each dimension. The overall half reliability of the scale was 0.923 and ranged from 0.834 to 0.935 for each dimension. 5 factors were extracted, with a cumulative variance contribution rate of 82.061%.Conclusions:Based on the HCAHPS framework in the United States, the Chronic Wound Debridement and Dressing Experience Scale developed has high reliability and validity, and can be used to evaluate the dressing change experience of patients with chronic wounds. It has clinical practice significance for dressing change in chronic wounds.
9.NIR-controlled transdermal delivery of atenolol based on polyethyleneimine-modified MoS2 nanoparticles
Yijian CUI ; Kai ZHANG ; Tianqi QIAO ; Xiaochang LIU
Journal of Shenyang Medical College 2024;26(1):11-17
Objective:Using atenolol as a model drug,the aim of this study was to develop a sustained and controlled transdermal drug delivery system(TDDS)based on polyethyleneimine-modified MoS2 nanoparticles(PEI-MoS2 NPs)that were responsive to near infrared(NIR)laser irradiation.Methods:The three-dimensional flower-like PEI-MoS2 NPs were successfully synthesized and further characterized by attenuated total reflection Fourier transform infrared spectroscopy,X-ray diffraction measurements,scanning electron microscopy,and transmission electron microscopy.The controlled release capacity of PEI-MoS2 NPs was examined using in vitro drug release and skin penetration experiments.Results:The PEI-MoS2 NPs exhibited a drug loading efficiency of 53.86% and high photothermal conversion ability.Moreover,the release of atenolol was enhanced by NIR stimulation with an enhancement ratio of 1.56.Conclusion:NIR-controlled PEI-MoS2 NPs was essential for the control and sustained release of drugs in TDDS.
10.Long-term prognosis analysis of chronic hepatitis B patients followed up for 25 years:Retrospective cohort study
Xiaoya YANG ; Tianqi HONG ; Kaili GE ; Renjie ZHANG ; Chunshan WEI
The Journal of Practical Medicine 2024;40(7):962-965,971
Objective To investigate the effect of age on the incidence of cirrhosis and liver cancer in patients with chronic hepatitis B.Methods 279 patients with chronic hepatitis B were divided into the senior group and the younger group according to the age of the patients.The cumulative incidence of cirrhosis and liver cancer during 25 years of follow-up was calculated by using SPSS and R language through the long-term follow-up of HIS system,and the risk factors were analyzed by multivariate logistic regression.Results During follow-up,24 cases developed cirrhosis and 12 cases developed liver cancer.The cumulative incidence of liver cirrhosis was 1.5%,2.1%,5.4%,11.6%and 15.5%in the 5-year,10-year,15-year,20-year and 25-year group,and 5.5%,9.8%,22.9%,29.0%and 52.1%in the elderly,respectively.The difference between the younger age group and senior age group was statistically significant(P<0.001).A total of 2 risk factors(age and follow-up time)were included in the regression model.Two cases in the younger group developed into liver cancer after 17 and 21 years of follow-up,respectively.The cumulative incidence rates at 5,10,15,20 and 25 years were 1.8%,3.8%,18.5%,21.8%and 26.7%.A total of five factors(initial age,HBV-DNA load,HBV-DNA turned negative before the end-point,follow-up time,and sex)were included in the regression model.Conclusions The incidence of cirrhosis and liver cancer in CHB patients aged≥40 years,especially in male patients,is significantly higher than younger CHB patients.Timely initiation of antiviral therapy can delay disease progression and reduce the incidence of termi-nal liver disease.Whether antiviral therapy should be initiated for people aged 30 to 40 years remains to be studied.

Result Analysis
Print
Save
E-mail